Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions

Camostat mesylate, a potent inhibitor of the human transmembrane protease, serine 2 (TMPRSS2), is currently under investigation for its effectiveness in COVID-19 patients. For its safe application, the risks of camostat mesylate to induce pharmacokinetic drug-drug interactions with co-administered d...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Johanna, Bajraktari-Sylejmani, Gzona, Haefeli, Walter Emil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748837/
https://www.ncbi.nlm.nih.gov/pubmed/33647240
http://dx.doi.org/10.1016/j.cbi.2021.109428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748837/
https://www.ncbi.nlm.nih.gov/pubmed/33647240
http://dx.doi.org/10.1016/j.cbi.2021.109428

Ejemplares similares